Flagship fledging fetches $50M to fire drugs at specific organs, fix on-target, off-tissue toxicity

Flagship Pioneering is back with a new biotech designed to tackle a key drug development challenge: on-target, off-tissue toxicity. By creating drugs that only act at the diseased tissue, regardless of whether a target is expressed elsewhere, the biotech aims to provide powerful punches without the side effects.